niacin has been researched along with Cardiovascular Stroke in 49 studies
Niacin: A water-soluble vitamin of the B complex occurring in various animal and plant tissues. It is required by the body for the formation of coenzymes NAD and NADP. It has PELLAGRA-curative, vasodilating, and antilipemic properties.
vitamin B3 : Any member of a group of vitamers that belong to the chemical structural class called pyridines that exhibit biological activity against vitamin B3 deficiency. Vitamin B3 deficiency causes a condition known as pellagra whose symptoms include depression, dermatitis and diarrhea. The vitamers include nicotinic acid and nicotinamide (and their ionized and salt forms).
nicotinic acid : A pyridinemonocarboxylic acid that is pyridine in which the hydrogen at position 3 is replaced by a carboxy group.
| Excerpt | Relevance | Reference |
|---|---|---|
| " In the present study, we sought to assess the effect of extended-release niacin/laropiprant on endothelial function in patients after a myocardial infarction with target low-density lipoprotein cholesterol (LDL-C)." | 9.19 | Extended-release niacin/laropiprant improves endothelial function in patients after myocardial infarction. ( Bregar, U; Cevc, M; Jug, B; Keber, I; Sebestjen, M, 2014) |
| "This post hoc analysis from the Coronary Drug Project (CDP) evaluated the effects of niacin monotherapy on clinical outcomes in patients with and without the metabolic syndrome (MS)." | 9.12 | Benefits of niacin in patients with versus without the metabolic syndrome and healed myocardial infarction (from the Coronary Drug Project). ( Canner, PL; Furberg, CD; McGovern, ME, 2006) |
| " In our study, patients were randomized, on average, 6 days after an acute myocardial infarction and/or percutaneous transluminal coronary angioplasty secondary to unstable angina, to pravastatin (combined, when necessary, with cholestyramine and/or nicotinic acid) to achieve low-density lipoprotein cholesterol levels of < or =130 mg/dl (group A, n = 70)." | 9.09 | Beneficial effects of pravastatin (+/-colestyramine/niacin) initiated immediately after a coronary event (the randomized Lipid-Coronary Artery Disease [L-CAD] Study). ( Agrawal, R; Arntz, HR; Fischer, F; Schnitzer, L; Schultheiss, HP; Stern, R; Wunderlich, W, 2000) |
| "The use of niacin to improve plasma lipid levels and reduce risk of myocardial infarction is limited by noxious skin effects that result from stimulation of G protein-coupled receptor 109A (GPR109A) in skin immune cells." | 7.76 | Seeing red: flushing out instigators of niacin-associated skin toxicity. ( Dunbar, RL; Gelfand, JM, 2010) |
| " In the present study, we sought to assess the effect of extended-release niacin/laropiprant on endothelial function in patients after a myocardial infarction with target low-density lipoprotein cholesterol (LDL-C)." | 5.19 | Extended-release niacin/laropiprant improves endothelial function in patients after myocardial infarction. ( Bregar, U; Cevc, M; Jug, B; Keber, I; Sebestjen, M, 2014) |
| "This post hoc analysis from the Coronary Drug Project (CDP) evaluated the effects of niacin monotherapy on clinical outcomes in patients with and without the metabolic syndrome (MS)." | 5.12 | Benefits of niacin in patients with versus without the metabolic syndrome and healed myocardial infarction (from the Coronary Drug Project). ( Canner, PL; Furberg, CD; McGovern, ME, 2006) |
| " In our study, patients were randomized, on average, 6 days after an acute myocardial infarction and/or percutaneous transluminal coronary angioplasty secondary to unstable angina, to pravastatin (combined, when necessary, with cholestyramine and/or nicotinic acid) to achieve low-density lipoprotein cholesterol levels of < or =130 mg/dl (group A, n = 70)." | 5.09 | Beneficial effects of pravastatin (+/-colestyramine/niacin) initiated immediately after a coronary event (the randomized Lipid-Coronary Artery Disease [L-CAD] Study). ( Agrawal, R; Arntz, HR; Fischer, F; Schnitzer, L; Schultheiss, HP; Stern, R; Wunderlich, W, 2000) |
| "Moderate- to high-quality evidence suggests that niacin does not reduce mortality, cardiovascular mortality, non-cardiovascular mortality, the number of fatal or non-fatal myocardial infarctions, nor the number of fatal or non-fatal strokes but is associated with side effects." | 4.95 | Niacin for primary and secondary prevention of cardiovascular events. ( Arpagaus, A; Briel, M; Hemkens, LG; Nordmann, AJ; Olu, KK; Saccilotto, R; Schandelmaier, S, 2017) |
| "Therapeutic benefit of niacin, fibrates, and cholesteryl ester transfer protein (CETP) inhibitors on cardiovascular events (all cause mortality, coronary heart disease mortality, non-fatal myocardial infarction, and stroke)." | 4.90 | Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117,411 patients. ( Francis, DP; Keene, D; Price, C; Shun-Shin, MJ, 2014) |
| "The use of niacin to improve plasma lipid levels and reduce risk of myocardial infarction is limited by noxious skin effects that result from stimulation of G protein-coupled receptor 109A (GPR109A) in skin immune cells." | 3.76 | Seeing red: flushing out instigators of niacin-associated skin toxicity. ( Dunbar, RL; Gelfand, JM, 2010) |
| "Results of recent clinical trials on secondary prevention of ischemic heart disease indicate that judicious, long-term administration of adrenergic beta blockers and platelet-active drugs such as aspirin and Persantine (dipyridamole) would seem to yield protection against mortality associated with acute myocardial infarction, including sudden death." | 3.67 | Clinical trials on the efficacy of pharmacologic intervention reducing mortality from cardiovascular diseases. ( Borhani, NO, 1985) |
| "Niacin has potentially favourable effects on lipids, but its effect on cardiovascular outcomes is uncertain." | 2.78 | HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. ( , 2013) |
| "placebo on the incidence of new onset type 2 diabetes mellitus (T2DM) and cardiovascular event rates in patients with normal and impaired fasting glucose (IFG)." | 2.78 | Effects of niacin on the incidence of new onset diabetes and cardiovascular events in patients with normoglycaemia and impaired fasting glucose. ( Canner, PL; Maccubbin, D; Sazonov, V; Sisk, CM, 2013) |
| "Niacin treatment showed modest benefit in decreasing definite nonfatal recurrent myocardial infarction but did not decrease total mortality." | 2.66 | Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. ( Berge, KG; Canner, PL; Friedewald, W; Friedman, L; Prineas, RJ; Stamler, J; Wenger, NK, 1986) |
| "Niacin has been studied in 6 major clinical trials with cardiovascular endpoints." | 2.40 | Effect of niacin on atherosclerotic cardiovascular disease. ( Guyton, JR, 1998) |
| "Recent studies suggest that treating dyslipidemia in persons with coronary atherosclerosis may decrease morbidity and mortality." | 2.39 | Number-needed-to-treat analysis of the prevention of myocardial infarction and death by antidyslipidemic therapy. ( Rembold, CM, 1996) |
| "Niacin was started after recurrence." | 1.36 | Case report. Hyperlipoproteinaemia(a): which is the optimal therapy? A case report. ( Lupattelli, G; Mannarino, E; Roscini, AR; Siepi, D, 2010) |
| "Would the money spent on treating hypercholesterolemia save more lives if spent elsewhere? How many dollars must be spent on a treatment to make one person live 1 year longer? This cost-effectiveness analysis uses the cost per year of life gained to compare a wide variety of health care interventions ranging from carcinogen research to screening tests to liver transplants." | 1.28 | Hypercholesterolemia: the cost of treatment in perspective. ( Kelley, MD, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 15 (30.61) | 18.7374 |
| 1990's | 5 (10.20) | 18.2507 |
| 2000's | 13 (26.53) | 29.6817 |
| 2010's | 16 (32.65) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Schandelmaier, S | 1 |
| Briel, M | 1 |
| Saccilotto, R | 1 |
| Olu, KK | 1 |
| Arpagaus, A | 1 |
| Hemkens, LG | 1 |
| Nordmann, AJ | 1 |
| Ponce, OJ | 1 |
| Larrea-Mantilla, L | 1 |
| Hemmingsen, B | 1 |
| Serrano, V | 1 |
| Rodriguez-Gutierrez, R | 1 |
| Spencer-Bonilla, G | 1 |
| Alvarez-Villalobos, N | 1 |
| Benkhadra, K | 1 |
| Haddad, A | 1 |
| Gionfriddo, MR | 1 |
| Prokop, LJ | 1 |
| Brito, JP | 1 |
| Murad, MH | 1 |
| Sazonov, V | 1 |
| Maccubbin, D | 1 |
| Sisk, CM | 1 |
| Canner, PL | 4 |
| Bregar, U | 1 |
| Jug, B | 1 |
| Keber, I | 1 |
| Cevc, M | 1 |
| Sebestjen, M | 1 |
| Kleber, ME | 1 |
| Grammer, TB | 1 |
| Kassner, U | 1 |
| Silbernagel, G | 1 |
| März, W | 1 |
| Keene, D | 1 |
| Price, C | 1 |
| Shun-Shin, MJ | 1 |
| Francis, DP | 1 |
| Verdoia, M | 1 |
| Schaffer, A | 1 |
| Suryapranata, H | 1 |
| De Luca, G | 1 |
| Mitręga, KA | 1 |
| Nożyński, J | 1 |
| Porc, M | 1 |
| Spałek, AM | 1 |
| Krzemiński, TF | 1 |
| Albers, JJ | 1 |
| Slee, A | 1 |
| Fleg, JL | 1 |
| O'Brien, KD | 1 |
| Marcovina, SM | 1 |
| Krumholz, HM | 1 |
| Silverman, MG | 1 |
| Ference, BA | 1 |
| Im, K | 1 |
| Wiviott, SD | 1 |
| Giugliano, RP | 1 |
| Grundy, SM | 1 |
| Braunwald, E | 1 |
| Sabatine, MS | 1 |
| Hill, AM | 1 |
| Fleming, JA | 1 |
| Kris-Etherton, PM | 1 |
| Duggal, JK | 1 |
| Singh, M | 1 |
| Attri, N | 1 |
| Singh, PP | 1 |
| Ahmed, N | 1 |
| Pahwa, S | 1 |
| Molnar, J | 1 |
| Singh, S | 1 |
| Khosla, S | 1 |
| Arora, R | 1 |
| Dunbar, RL | 1 |
| Gelfand, JM | 1 |
| Lupattelli, G | 1 |
| Roscini, AR | 1 |
| Siepi, D | 1 |
| Mannarino, E | 1 |
| Schaefer, JR | 1 |
| JAROSCHEWSKI, AJ | 1 |
| SHAWORONKOWA, EK | 1 |
| KOBAYASHI, T | 1 |
| TAKEUCHI, M | 1 |
| FAZEKAS, JF | 1 |
| ALMAN, RW | 1 |
| TICKTIN, HE | 1 |
| EHRMANTRAUT, WR | 1 |
| SAVARESE, CJ | 1 |
| IAROSHEVSKII, AIa | 1 |
| ZHAVORONKOVA, EK | 1 |
| BOEHME, H | 1 |
| SCOPPOLA, L | 1 |
| GANDINI, L | 1 |
| GENARD, P | 1 |
| Furberg, CD | 2 |
| Terrin, ML | 1 |
| McGovern, ME | 2 |
| Goldstein, MR | 1 |
| Schwiesow, SJ | 1 |
| Nappi, JM | 1 |
| Ragucci, KR | 1 |
| Veryard, C | 1 |
| Hanefeld, M | 1 |
| Hora, C | 1 |
| Schulze, J | 1 |
| Rothe, G | 1 |
| Barthel, U | 1 |
| Haller, H | 1 |
| Rembold, CM | 1 |
| Holme, I | 1 |
| Guyton, JR | 1 |
| Arntz, HR | 2 |
| Wunderlich, W | 2 |
| Schnitzer, L | 2 |
| Stern, R | 2 |
| Fischer, F | 2 |
| Agrawal, R | 2 |
| Linderer, T | 1 |
| Schultheiss, HP | 2 |
| Mack, WJ | 1 |
| Xiang, M | 1 |
| Selzer, RH | 1 |
| Hodis, HN | 1 |
| Sprecher, DL | 1 |
| Klungel, OH | 1 |
| Heckbert, SR | 1 |
| de Boer, A | 1 |
| Leufkens, HG | 1 |
| Sullivan, SD | 1 |
| Fishman, PA | 1 |
| Veenstra, DL | 1 |
| Psaty, BM | 1 |
| Kelley, MD | 1 |
| Mamedov, IaD | 1 |
| Garaev, GSh | 1 |
| Korkmazov, BM | 1 |
| Mirzabekova, FI | 1 |
| Borhani, NO | 1 |
| Rudzite, V | 1 |
| Jirgensons, J | 1 |
| Jurika, E | 1 |
| Sileniece, G | 1 |
| Zirne, R | 1 |
| Jirgensone, S | 1 |
| Vik-Mo, H | 1 |
| Mjøs, OD | 1 |
| Neely, JR | 1 |
| Maroko, PR | 1 |
| Ribeiro, LG | 1 |
| Berge, KG | 1 |
| Wenger, NK | 1 |
| Stamler, J | 1 |
| Friedman, L | 1 |
| Prineas, RJ | 1 |
| Friedewald, W | 1 |
| Walldius, G | 1 |
| Wahlberg, G | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Double-Blind, Parallel Group Study to Evaluate the Efficacy and Safety of Bempedoic Acid 180 Mg + Ezetimibe 10 Mg Fixed-Dose Combination Compared to Bempedoic Acid, Ezetimibe, and Placebo Alone in Patients Treated With Maximally Tolerated St[NCT03337308] | Phase 3 | 382 participants (Actual) | Interventional | 2017-10-23 | Completed | ||
| A Randomized Controlled Intervention Study to Assess the Effect of Bergamot Juice on LDL Cholesterol Level in Healthy Subjects[NCT05589636] | 44 participants (Anticipated) | Interventional | 2022-02-10 | Recruiting | |||
| Correlates of Angiographic Changes and Coronary Events: The Cholesterol-Lowering Atherosclerosis Study (CLAS)[NCT00005433] | 188 participants (Actual) | Observational | 1996-04-30 | Completed | |||
| [NCT00000483] | 0 participants | Interventional | 1981-06-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Blood samples were drawn after a minimum 10-hour fast (water was allowed) at pre-specified intervals. Samples were collected and analyzed for apo B. Baseline was defined as the predose Day 1/Week 0 value. Percent change from baseline in apo B was analyzed using ANCOVA with treatment group and randomization stratification as a factors and baseline apo B as a covariate. Percent change from baseline was calculated as: ([apo B value at Week 12 minus Baseline value] divided by [Baseline Value]) multiplied by 100. (NCT03337308)
Timeframe: Baseline; Week 12
| Intervention | Percent change (Least Squares Mean) |
|---|---|
| Bempedoic Acid 180 mg + Ezetimibe 10 mg FDC | -24.6 |
| Bempedoic Acid 180 mg | -11.8 |
| Ezetimibe 10 mg | -15.3 |
| Placebo | 5.5 |
Blood samples were drawn after a minimum 10-hour fast (water was allowed) at pre-specified intervals. Samples were collected and analyzed for HDL-C. Baseline was defined as the mean of the HDL-C values from Week -2 and predose Day 1/Week 0. Percent change from baseline was calculated as: ([HDL-C value at Week 12 minus Baseline value] divided by [Baseline Value]) multiplied by 100. (NCT03337308)
Timeframe: Baseline; Week 12
| Intervention | Percent change (Mean) |
|---|---|
| Bempedoic Acid 180 mg + Ezetimibe 10 mg FDC | -5.59 |
| Bempedoic Acid 180 mg | -5.40 |
| Ezetimibe 10 mg | -2.11 |
| Placebo | -0.54 |
Blood samples were drawn after a minimum 10-hour fast (water was allowed) at pre-specified intervals. Samples were collected and analyzed for hsCRP. Baseline was defined as the predose Day 1/Week 0 value. Percent change from baseline in hsCRP was analyzed using a non-parametric analysis. Percent change from baseline was calculated as: ([hsCRP value at Week 12 minus Baseline value] divided by [Baseline Value]) multiplied by 100. (NCT03337308)
Timeframe: Baseline; Week 12
| Intervention | Percent Change (Median) |
|---|---|
| Bempedoic Acid 180 mg + Ezetimibe 10 mg FDC | -35.1 |
| Bempedoic Acid 180 mg | -31.9 |
| Ezetimibe 10 mg | -8.2 |
| Placebo | 21.6 |
Blood samples were drawn after a minimum 10-hour fast (water was allowed) at pre-specified intervals. Samples were collected and analyzed for LDL-C. Baseline was defined as the mean of the LDL-C values from Week -2 and predose Day 1/Week 0. Percent change from baseline in LDL-C was analyzed using analysis of covariance (ANCOVA) with treatment group and randomization stratification as a factors and baseline LDL-C as a covariate. Percent change from baseline was calculated as: ([LDL-C value at Week 12 minus Baseline value] divided by [Baseline Value]) multiplied by 100. For LDL-C, if measured LDL-C value was available, measured LDL-C was used. (NCT03337308)
Timeframe: Baseline; Week 12
| Intervention | Percent Change (Least Squares Mean) |
|---|---|
| Bempedoic Acid 180 mg + Ezetimibe 10 mg FDC | -36.2 |
| Bempedoic Acid 180 mg | -17.2 |
| Ezetimibe 10 mg | -23.2 |
| Placebo | 1.8 |
Blood samples were drawn after a minimum 10-hour fast (water was allowed) at pre-specified intervals. Samples were collected and analyzed for non-HDL-C. Baseline was defined as the mean of the non-HDL-C values from Week -2 and predose Day 1/Week 0. Percent change from baseline in non-HDL-C was analyzed using ANCOVA with treatment group and randomization stratification as a factors and baseline non-HDL-C as a covariate. Percent change from baseline was calculated as: ([non-HDL-C value at Week 12 minus Baseline value] divided by [Baseline Value]) multiplied by 100. (NCT03337308)
Timeframe: Baseline; Week 12
| Intervention | Percent change (Least Squares Mean) |
|---|---|
| Bempedoic Acid 180 mg + Ezetimibe 10 mg FDC | -31.9 |
| Bempedoic Acid 180 mg | -14.1 |
| Ezetimibe 10 mg | -19.9 |
| Placebo | 1.8 |
Blood samples were drawn after a minimum 10-hour fast (water was allowed) at pre-specified intervals. Samples were collected and analyzed for TC. Baseline was defined as the mean of the TC values from Week -2 and predose Day 1/Week 0. Percent change from baseline in TC was analyzed using ANCOVA with treatment group and randomization stratification as a factors and baseline TC as a covariate. Percent change from baseline was calculated as: ([TC value at Week 12 minus Baseline value] divided by [Baseline Value]) multiplied by 100. (NCT03337308)
Timeframe: Baseline; Week 12
| Intervention | Percent change (Least Squares Mean) |
|---|---|
| Bempedoic Acid 180 mg + Ezetimibe 10 mg FDC | -26.4 |
| Bempedoic Acid 180 mg | -12.1 |
| Ezetimibe 10 mg | -16.0 |
| Placebo | 0.7 |
Blood samples were drawn after a minimum 10-hour fast (water was allowed) at pre-specified intervals. Samples were collected and analyzed for TGs. Baseline was defined as the mean of the TGs values from Week -2 and predose Day 1/Week 0. Percent change from baseline was calculated as: ([TGs value at Week 12 minus Baseline value] divided by [Baseline Value]) multiplied by 100. (NCT03337308)
Timeframe: Baseline; Week 12
| Intervention | Percent change (Mean) |
|---|---|
| Bempedoic Acid 180 mg + Ezetimibe 10 mg FDC | -7.90 |
| Bempedoic Acid 180 mg | 7.94 |
| Ezetimibe 10 mg | -2.46 |
| Placebo | 5.47 |
14 reviews available for niacin and Cardiovascular Stroke
| Article | Year |
|---|---|
Niacin for primary and secondary prevention of cardiovascular events.
Topics: Adult; Aged; Cardiovascular Diseases; Humans; Middle Aged; Myocardial Infarction; Niacin; Primary Pr | 2017 |
Lipid-Lowering Agents in Older Individuals: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.
Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Coronary Artery Disease; Diabetes Mellitus; Fibric | 2019 |
Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117,411 patients.
Topics: Amides; Anticholesteremic Agents; Cholesterol Ester Transfer Proteins; Coronary Disease; Esters; Fib | 2014 |
Effects of HDL-modifiers on cardiovascular outcomes: a meta-analysis of randomized trials.
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol Ester Transfer Proteins; Diabetes Mel | 2015 |
Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: A Systematic Review and Meta-analysis.
Topics: Cardiovascular Diseases; Cholesterol, LDL; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhib | 2016 |
Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: A Systematic Review and Meta-analysis.
Topics: Cardiovascular Diseases; Cholesterol, LDL; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhib | 2016 |
Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: A Systematic Review and Meta-analysis.
Topics: Cardiovascular Diseases; Cholesterol, LDL; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhib | 2016 |
Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: A Systematic Review and Meta-analysis.
Topics: Cardiovascular Diseases; Cholesterol, LDL; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhib | 2016 |
The role of diet and nutritional supplements in preventing and treating cardiovascular disease.
Topics: Cardiovascular Diseases; Diet; Dietary Supplements; Fish Oils; Humans; Hypolipidemic Agents; Life St | 2009 |
Effect of niacin therapy on cardiovascular outcomes in patients with coronary artery disease.
Topics: Cardiovascular Diseases; Coronary Artery Disease; Humans; Hypolipidemic Agents; Myocardial Infarctio | 2010 |
[HDL level or HDL function as the primary target in preventive cardiology].
Topics: Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Cholesterol Ester Transfer Proteins; Choles | 2012 |
CURRENT THERAPEUTIC CONCEPTS OF CEREBRAL AND MYOCARDIAL VASCULAR DISEASE.
Topics: Acetazolamide; Anticoagulants; Brain Ischemia; Cerebrovascular Disorders; Coronary Disease; Histamin | 1964 |
Number-needed-to-treat analysis of the prevention of myocardial infarction and death by antidyslipidemic therapy.
Topics: Coronary Angiography; Coronary Artery Disease; Disease Progression; Female; Humans; Hydroxymethylglu | 1996 |
Relationship between total mortality and cholesterol reduction as found by meta-regression analysis of randomized cholesterol-lowering trials.
Topics: Anticholesteremic Agents; Cholesterol; Clofibrate; Coronary Disease; Humans; Myocardial Infarction; | 1996 |
Effect of niacin on atherosclerotic cardiovascular disease.
Topics: Cerebrovascular Disorders; Coronary Artery Disease; Drug Therapy, Combination; Humans; Hypolipidemic | 1998 |
Raising high-density lipoprotein cholesterol with niacin and fibrates: a comparative review.
Topics: Cholesterol, HDL; Clinical Trials as Topic; Coronary Disease; Drug Combinations; Female; Gemfibrozil | 2000 |
Secondary prevention of coronary disease with lipid-lowering drugs.
Topics: Adult; Cholesterol; Clinical Trials as Topic; Coronary Disease; Double-Blind Method; Humans; Hypolip | 1989 |
10 trials available for niacin and Cardiovascular Stroke
| Article | Year |
|---|---|
HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment.
Topics: Arterial Occlusive Diseases; Chemical and Drug Induced Liver Injury; Death, Sudden, Cardiac; Delayed | 2013 |
Effects of niacin on the incidence of new onset diabetes and cardiovascular events in patients with normoglycaemia and impaired fasting glucose.
Topics: Blood Glucose; Coronary Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Meth | 2013 |
Extended-release niacin/laropiprant improves endothelial function in patients after myocardial infarction.
Topics: Adult; Biomarkers; Brachial Artery; Cholesterol, HDL; Delayed-Action Preparations; Double-Blind Meth | 2014 |
Relationship of baseline HDL subclasses, small dense LDL and LDL triglyceride to cardiovascular events in the AIM-HIGH clinical trial.
Topics: Aged; Anticholesteremic Agents; Cardiovascular Diseases; Cardiovascular System; Cholesterol, HDL; Co | 2016 |
Benefits of niacin in patients with versus without the metabolic syndrome and healed myocardial infarction (from the Coronary Drug Project).
Topics: Cholesterol, HDL; Follow-Up Studies; Humans; Hypolipidemic Agents; Metabolic Syndrome; Myocardial In | 2006 |
[Short- and long-term effects of intensified versus conventional antilipidemic therapy in patients with coronary heart disease. Results from the Lipid-Coronary Artery Disease (L-CAD) Study].
Topics: Adult; Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Cholesterol | 1999 |
Serial quantitative coronary angiography and coronary events.
Topics: Adult; Cholesterol, LDL; Colestipol; Collateral Circulation; Coronary Angiography; Coronary Artery D | 2000 |
Beneficial effects of pravastatin (+/-colestyramine/niacin) initiated immediately after a coronary event (the randomized Lipid-Coronary Artery Disease [L-CAD] Study).
Topics: Adult; Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Chemopreven | 2000 |
Secondary prevention of coronary disease with lipid-lowering drugs.
Topics: Adult; Cholesterol; Clinical Trials as Topic; Coronary Disease; Double-Blind Method; Humans; Hypolip | 1989 |
Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin.
Topics: Adult; Aspirin; Clofibrate; Dextrothyroxine; Estrogens; Follow-Up Studies; Humans; Male; Middle Aged | 1986 |
26 other studies available for niacin and Cardiovascular Stroke
| Article | Year |
|---|---|
Dusty punch cards and an eternal enigma: high-density lipoproteins and atherosclerosis.
Topics: Animals; Atherosclerosis; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Humans; Myocardial | 2014 |
Dihydropyridines' metabolites-induced early apoptosis after myocardial infarction in rats; new outlook on preclinical study with M-2 and M-3.
Topics: Animals; Apoptosis; Blood Pressure; Cardiotonic Agents; Drug Evaluation, Preclinical; Furans; Male; | 2016 |
Niacin: Time to Believe Outcomes Over Surrogate Outcomes: If Not Now, When?
Topics: Cholesterol, HDL; Humans; Hypolipidemic Agents; Myocardial Infarction; Niacin | 2016 |
[Treatment of dyslipoproteinemia risk factor. Lipid therapy must become multidimensional].
Topics: Cerebral Infarction; Cholesterol, HDL; Cholesterol, LDL; Dose-Response Relationship, Drug; Humans; H | 2008 |
Seeing red: flushing out instigators of niacin-associated skin toxicity.
Topics: Cyclooxygenase 2; Dyslipidemias; Flushing; Fumarates; Humans; Myocardial Infarction; Niacin; Recepto | 2010 |
Case report. Hyperlipoproteinaemia(a): which is the optimal therapy? A case report.
Topics: Cholesterol, HDL; Cholesterol, LDL; Clofibric Acid; Fluorobenzenes; Humans; Hydroxymethylglutaryl-Co | 2010 |
[COAGULATION AND ANTICOAGULATION FACTORS IN THE BLOOD AND THEIR ALTERATION IN DISORDERS OF CORONARY CIRCULATION].
Topics: Angina Pectoris; Blood Coagulation; Blood Coagulation Disorders; Blood Coagulation Factors; Coronary | 1963 |
[REHABILITATION IN HEART DISEASE].
Topics: Acenocoumarol; Dipyridamole; Electrocardiography; Geriatrics; Heart Defects, Congenital; Heart Disea | 1963 |
[COAGULATION AND ANTICOAGULATION SYSTEM OF THE BLOOD AND ITS REACTION TO CORONARY CIRCULATION DISORDERS].
Topics: Angina Pectoris; Anticoagulants; Blood Coagulation Disorders; Blood Coagulation Tests; Coronary Circ | 1964 |
[DIFFERENTIAL THERAPEUTIC INDICATIONS AND CONTRAINDICATION FOR THE USE OF DRUGS CORRECTING CARDIAC ARRHYTHMIA].
Topics: Arrhythmias, Cardiac; Brugada Syndrome; Cardiac Conduction System Disease; Digitalis Glycosides; Dru | 1964 |
[First results with nialamide in cardiovascular therapy].
Topics: Anti-Arrhythmia Agents; Coronary Disease; Humans; Myocardial Infarction; Niacin; Nialamide; Nicotini | 1959 |
[HDL cholesterol as protective factor. Deficiency threatens the diabetic heart].
Topics: Cholesterol, HDL; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Humans; Hyperlipidemias; Hypo | 2003 |
[Even if LDL and triglycerides are within normal limits, low HDL increases risk of infarction].
Topics: Cholesterol, HDL; Cholesterol, LDL; Delayed-Action Preparations; Humans; Life Style; Myocardial Infa | 2004 |
[Results of the treatment of myocardial infarct by nicotinic acid compared to the results of the classic treatment; study of a few personal cases].
Topics: Heart; Humans; Myocardial Infarction; Niacin; Nicotinic Acids | 1950 |
Benefits of niacin by glycemic status in patients with healed myocardial infarction (from the Coronary Drug Project).
Topics: Blood Glucose; Florida; Follow-Up Studies; Humans; Hypolipidemic Agents; Male; Maryland; Myocardial | 2005 |
Use of niacin during non-ST-segment elevation acute coronary syndromes.
Topics: Angina, Unstable; Contraindications; Humans; Hypolipidemic Agents; Myocardial Infarction; Niacin | 2005 |
Assessment of compliance with lipid guidelines in an academic medical center.
Topics: Academic Medical Centers; American Heart Association; Angioplasty, Balloon, Coronary; Cerebrovascula | 2006 |
American Heart Association - Scientific Sessions 2006. Cell therapies for ischemic tissues and treatments for lipid metabolism disorders.
Topics: Animals; Cell- and Tissue-Based Therapy; Cholesterol, LDL; Coronary Disease; Endothelial Cells; Eryt | 2007 |
Reduced incidence of cardiovascular complications and mortality in hyperlipoproteinemia (HLP) with effective lipid correction. The Dresden HLP study.
Topics: Adolescent; Adult; Cerebrovascular Disorders; Cholesterol; Cholestyramine Resin; Clofibrate; Combine | 1984 |
Lipid-lowering drug use and cardiovascular events after myocardial infarction.
Topics: Cholesterol; Clofibrate; Cohort Studies; Coronary Artery Disease; Coronary Disease; Female; Humans; | 2002 |
Hypercholesterolemia: the cost of treatment in perspective.
Topics: Adult; Aged; Child; Cost-Benefit Analysis; Dietary Fiber; Electrocardiography; Evaluation Studies as | 1990 |
[The structuro-functional state of the ischemic myocardium under the action of a terrilitin-nicotinic acid mixture in animal experiments].
Topics: Amylases; Animals; Drug Combinations; Myocardial Infarction; Myocardium; Necrosis; Niacin; Peptide H | 1988 |
Clinical trials on the efficacy of pharmacologic intervention reducing mortality from cardiovascular diseases.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Aspirin; Cardiovascular Diseases; Clofibrate; | 1985 |
[Peculiarities of nicotinic acid formation in coronary heart disease with special reference to heart arrhythmias].
Topics: Angina Pectoris; Animals; Arrhythmias, Cardiac; Coronary Disease; Female; Humans; Kynurenine; Lipid | 1988 |
Limitation of myocardial infarct size by metabolic interventions that reduce accumulation of fatty acid metabolites in ischemic myocardium.
Topics: Acetylcarnitine; Acyl Coenzyme A; Adenine Nucleotides; Animals; Dogs; Drug Synergism; Drug Therapy, | 1986 |
Effects of nicotinic acid and its derivatives on lipid metabolism and other metabolic factors related to atherosclerosis.
Topics: Animals; Apolipoproteins; Arteriosclerosis; Bile Acids and Salts; Carbohydrate Metabolism; Cholester | 1985 |